Table 1.
Age, matrix metalloprotease (MMP) and tissue inhibitors (TIMP) plasma values of the patients according to diagnostic categories and gender*
| All patients (n = 389) | HIV+/HCV+ (n = 111) | HIV+/HCV– (n = 102) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Male (n = 253) | Female (n = 136) | P | Male (n = 75) | Female (n = 36) | P | Male (n = 69) | Female (n = 33) | P | |
| Age (years) | 47·0 (40·5–58·0) | 49·0 (42·0–65·0) | 0·3 | 44·0 (40·0–48·0) | 44·0 (41·3–47·0) | 0·9 | 45·0 (40·0-52·0) | 44·0 (38·0-52·0) | 0·6 |
| MMP-1 | 29·9 (11·6–57·8) | 23·5 (12·7–41·3) | 0·3 | 38·4 (18·8–64·7) | 4·6 (2·7–75·3) | 0·06 | 3·9 (2·4-11·6) | 10·9 (3·2300-73·5) | 0·5 |
| MMP-2 | 0·76 (0·43–1·33) | 0·82 (0·44–1·48) | 0·6 | 0·88 (0·57–1·28) | 0·96 (0·48–1·38) | 0·7 | 0·48 (0·22-0·83) | 0·85 (0·24-1·51) | 0·3 |
| MMP-3 | 18·3 (10·8–33·1) | 11·31 (5·9–19·0) | <0·0001 | 17·6 (13·4–31·7) | 13·7 (7·3–22·3) | 0·049 | 16·5 (10·0-27·2) | 8·8 (5·4-16·3) | 0·0007 |
| MMP-8 | 0·87 (0·03–26·18) | 0·97 (0·02–34·4) | 0·9 | 0·04 (0·02–0·14) | 0·03 (0·01–0·05) | 0·08 | 0·03 (0·02-0·05) | 0·015 (0·01-0·03) | 0·003 |
| MMP-9 | 87·3 (22·3–565·5) | 99·0 (18·3–546·0) | 0·5 | 29·2 (12·0–54·0) | 13·6 (6·5–30·4) | 0·01 | 21·9 (11·3-52·2) | 24·5 (9·5-36·7) | 0·6 |
| MMP-10 | 11·22 (2·19–47·69) | 24·60 (3·33–75·18) | 0·08 | 2·05 (0·84–5·89) | 2·21 (0·83–3·16) | 0·9 | 1·50 (0·76-2·68) | 2·24 (0·98-4·42) | 0·2 |
| MMP-13 | 0·11 (0·06–0·31) | 0·12 (0·06–0·25) | 0·8 | 0·59 (0·07–1·64) | 0·12 (0·06–0·13) | 0·3 | 0·07 (0·02-0·19) | 0·13 (0·05-0·22) | 0·5 |
| TIMP-1 | 129·9 (53·3–262·2) | 146·1 (49·3–251·7) | 0·6 | 59·2 (38·3–75·9) | 47·8 (29·3–71·4) | 0·1 | 51·5 (36·4-75·4) | 49·4 (29·4-65·1) | 0·3 |
| TIMP-2 | 22·5 (7·9–89·6) | 31·4 (7·9–87·9) | 0·97 | 8·5 (5·9–13·4) | 8·8 (5·9–12·3) | 0·7 | 8·7 (5·2-11·3) | 7·6 (3·0-12·0) | 0·2 |
| TIMP-4 | 0·55 (0·05–2·95) | 1·36 (0·11–4·25) | 0·047 | 0·06 (0·03–0·17) | 0·09 (0·03–0·25) | 0·4 | 0·04 (0·02-0·09) | 0·09 (0·04-0·24) | 0·005 |
| Septics (n = 90) | Stroke (n = 45) | Trauma (n = 41) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Male (n = 50) | Female (n = 40) | P | Male (n = 26) | Female (n = 19) | P | Male (n = 33) | Female (n = 8) | P | |
| Age (years) | 58·0 (45·8–72·0) | 65·0 (41·3–75·0) | 0·5 | 68·0 (56·0–72·3) | 65·0 (59·0–74·0) | 0·8 | 50·0 (35·0-65·0) | 60·5 (39·5-68·8) | 0·4 |
| MMP-1 | 34·3 (19·9–72·1) | 22·8 (11·8–36·2) | 0·03 | 33·7 (19·0–54·7) | 37·7 (22·5–55·5) | 0·6 | 19·6 (5·35-52·5) | 20·2 (13·5-56·7) | 0·4 |
| MMP-2 | 1·08 (0·54–2·59) | 0·69 (0·50–2·22) | 0·3 | 0·73 (0·44–1·37) | 0·76 (0·47–1·54) | 0·9 | 0·64 (0·32-1·98) | 0·59 (0·28-1·39) | 0·7 |
| MMP-3 | 36·0 (16·06–74·0) | 14·1 (9·5–23·5) | 0·0001 | 12·6 (7·0–22·3) | 5·9 (4·3–12·2) | 0·01 | 13·4 (7·9-26·7) | 5·8 (3·9-9·1) | 0·003 |
| MMP-8 | 48·7 (34·0–75·2) | 43·5 (32·4–70·2) | 0·5 | 12·9 (9·0–25·1) | 13·8 (9·5–25·3) | 0·8 | 14·7 (8·3-26·4) | 15·7 (4·0-29·0) | 0·7 |
| MMP-9 | 467·7 (226·4–641·3) | 362·8 (165·7–587·4) | 0·17 | 660·0 (530·3–1012·2) | 719·9 (643·0–920·5) | 0·3 | 630·4 (387·1-852·3) | 538·3 (246·2-690·2) | 0·4 |
| MMP-10 | 44·9 (11·6–147·5) | 82·7 (36·7–186·8) | 0·03 | 34·9 (11·9–96·4) | 23·6 (8·0–27·9) | 0·12 | 16·7 (10·4-45·4) | 10·2 (8·6-33·2) | 0·3 |
| MMP-13 | 0·16 (0·08–0·26) | 0·16 (0·08–0·28) | 0·8 | 0·12 (0·05–0·38) | 0·07 (0·04–0·39) | 0·5 | 0·06 (0·04-0·26) | 0·04 (0·03-0·35) | 0·5 |
| TIMP-1 | 265·5 (233·2–314·6) | 246·9 (222·6–285·9) | 0·15 | 264·7 (224·2–309·5) | 255·9 (225·8–308·4) | 0·8 | 263·3 (201·5-304·0) | 237·6 (169·8-315·2) | 0·7 |
| TIMP-2 | 104·8 (74·4–128·5) | 92·9 (68·3–124·4) | 0·4 | 88·3 (50·1–140·5) | 68·7 (52·6–119·2) | 0·6 | 77·9 (61·0-89·4) | 67·0 (45·6-115·5) | 0·7 |
| TIMP-4 | 3·43 (2·05–6·38) | 4·06 (2·10–7·78) | 0·6 | 3·89 (2·15–8·32) | 4·25 (2·17–5·80) | 0·8 | 2·43 (1·24-3·63) | 2·05 (1·35-3·71) | 0·7 |
*
MMPs and TIMPs are expressed as ng/ml. HIV+ = human immunodeficiency virus infection; HCV+ = hepatitis C virus infection. HIV+/HCV− and HIV+/HCV+ were anti-retroviral (ART)-treated.